Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
Junshi Biosciences has received acceptance from China’sNational Medical Products Administration (NMPA) for toripalimab ...
The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP. She also explained how the ...
ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses.
GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
A new study finds that GLP-1 drugs may help to stabilize chronic migraines, with patients seeing fewer ER visits and less need for additional medication.
Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.
From standard medications to advanced drug delivery, surgery, and regenerative approaches, Parkinson's treatment options in ...
Glenis Scadding still remembers one of her first patients for sublingual immunotherapy, forty years later. His hay fever was so debilitating that he couldn't walk to the local train station without ...
As NAD+ injections and IV drips trend from TikTok to the Kardashians, the science of longevity remains a work in progress. Explore the benefits, side effects, and the debate between oral precursors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results